P0F.F EGETIS THERAPEUTICS AB
- Market cap
- EUR 453M
- P/E
- -
- P/B
- 14.03x
- ROE
- -137.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is P0F.F undervalued?
Graham numberThe Graham number of EGETIS THERAPEUTICS AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EGETIS THERAPEUTICS AB fundamental analysis
No fundamental analysis for EGETIS THERAPEUTICS AB yet.
EGETIS THERAPEUTICS AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EGETIS THERAPEUTICS AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was form…
Full company profileEGETIS THERAPEUTICS AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EGETIS THERAPEUTICS AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 38.3M | 22.5M | 57.6M | 46.1M | 62.4M | 69.7M |
| Gross Profit | -58.3M | -120M | 46.6M | 34.5M | 12.4M | 7.07M |
| Operating Income | -105M | -197M | -311M | -322M | -330M | -450M |
| EBITDA | - | -191M | -319M | -322M | -290M | -446M |
| Net Income | -105M | -194M | -327M | -344M | -343M | -467M |
| EPS | -0.58 | -0.90 | -1.12 | -0.96 | -0.87 | -1.00 |
| Balance Sheet | ||||||
| Total Assets | 569M | 561M | 760M | 792M | 639M | 655M |
| Total Liabilities | 42.3M | 54.9M | 215M | 299M | 300M | 315M |
| Shareholders' Equity | 527M | 506M | 546M | 493M | 339M | 340M |
| Cash & Short-term Investments | 144M | 128M | 303M | 351M | 216M | 267M |
| Cash Flow | ||||||
| Operating Cash Flow | -130M | -174M | -278M | -228M | -267M | -345M |
| Capital Expenditure | 200K | 0.00 | 0.00 | 0.00 | 1.50M | 1.33M |
| Free Cash Flow | -130M | -174M | -278M | -228M | -269M | -346M |
| Ratios | ||||||
| ROE | -19.8% | -38.3% | -59.9% | -69.7% | -101.2% | -137.4% |
| ROA | -18.4% | -34.5% | -43.0% | -43.4% | -53.6% | -71.3% |
| Net Profit Margin | -272.8% | -861.3% | -567.5% | -745.3% | -548.9% | -670.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EGETIS THERAPEUTICS AB dividends
EGETIS THERAPEUTICS AB has not paid dividends in the last 5 fiscal years.
Who owns EGETIS THERAPEUTICS AB
- Insiders 23.39%
- Institutions 55.10%
- Public & others 21.51%
- Shares outstanding 465M
- Free float 240M
EGETIS THERAPEUTICS AB company profile
- Company name
- EGETIS THERAPEUTICS AB
- Ticker
- P0F.F
- ISIN
- SE0003815604
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Fiscal year end
- December
- Address
- Klara Norra Kyrkogata 26, Stockholm, Sweden, 111 22
- Phone
- 46 86 79 72 10
- Website
- egetis.com
About EGETIS THERAPEUTICS AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
EGETIS THERAPEUTICS AB management
10- Mr. Nicklas WesterholmChief Executive Officer · born 1976
- Mr. Torsten AlménFounder
- Dr. Ingemar Lundström Ph.D.Founder · born 1943
- Dr. Louis Joseph Ignarro Ph.D.Founder · born 1942
- Associate Prof. Heidi BrurokFounder
- Dr. Rob TowartFounder
- Dr. Yilmaz Mahshid Ph.D.Chief Financial Officer · born 1979
- Dr. Katayoun Welin-Berger Ph.D.Vice President of Operations · born 1968
- Dr. Karl Hard Ph.D.Head of Investor Relations & Business Development · born 1962
- Ms. Laetitia Szaller L.L.M.General Counsel & Head of Compliance